Innovative test being developed to predict type 2 diabetes risk

A pioneering new test is being developed to identify a person’s chances of developing type 2 diabetes.
American firm SomaLogic measures proteins in DNA to provide a unique blueprint of an individual’s health, as well as insights about their health requirements.
The SOMAscan uses proteins to provide a real-time picture of what is happening in our bodies, and serves as an indicator of prospective problems.
Now, the Leeds Centre for Personalised Medicine and Health have partnered up with SomaLogic to ascertain whether someone is likely to develop type 2 diabetes.
If successful, it is hoped the product could help doctors tailor their approach to each individual person in a bid to avoid a type 2 diabetes diagnosis.
Dr Mike Messenger, from the Leeds Centre for Personalised Medicine and Health, said: “A greater understanding of individuals’ current and future health needs means GPs can provide the most effective advice to stay healthy.
“In some cases the evidence may point to more regular monitoring of a patient or advice about lifestyle changes; for others, it might mean medication or treatment at an earlier stage. This is important research which could help to improve the health of people across Leeds for years to come.”
Lifestyle in particular is proving an essential method of preventing type 2 diabetes from developing, even among people with prediabetes.
Our Low Carb Program has helped thousands of people avoid a type 2 diabetes diagnosis and even help those with the condition come off their medication.
Dr Yvette Oade, chief medical officer for Leeds Teaching Hospitals NHS Trust, added: “Research and innovation is at the heart of everything we do in Leeds Teaching Hospitals as we know it brings better outcomes for patients.
“Personalised medicine is an area of growth and this innovation which might allow us to understand the potential to predict and even prevent disease before it occurs is particularly exciting.”